About Exelixis, Inc.
https://www.exelixis.comExelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.
CEO
Michael M. Morrissey
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 306
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
TD Cowen
Buy
Truist Securities
Buy
Citigroup
Buy
JMP Securities
Market Outperform
Leerink Partners
Outperform
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:33.5M
Value:$1.52B
BLACKROCK, INC.
Shares:29.37M
Value:$1.33B
VANGUARD GROUP INC
Shares:26.06M
Value:$1.18B
Summary
Showing Top 3 of 770
About Exelixis, Inc.
https://www.exelixis.comExelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $597.75M ▲ | $342.64M ▲ | $193.58M ▲ | 32.38% ▼ | $0.72 ▲ | $259.83M ▲ |
| Q2-2025 | $568.26M ▲ | $335.21M ▼ | $184.85M ▲ | 32.53% ▲ | $0.68 ▲ | $237.76M ▲ |
| Q1-2025 | $555.45M ▼ | $349.42M ▼ | $159.62M ▲ | 28.74% ▲ | $0.57 ▲ | $194.2M ▲ |
| Q4-2024 | $566.75M ▲ | $383.58M ▼ | $139.86M ▲ | 24.68% ▲ | $0.48 ▲ | $171.1M ▼ |
| Q3-2024 | $539.54M | $386.14M | $117.97M | 21.87% | $0.41 | $195.3M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $988.53M ▲ | $2.82B ▲ | $662.85M ▲ | $2.16B ▲ |
| Q2-2025 | $791.1M ▼ | $2.68B ▼ | $644.54M ▼ | $2.03B ▼ |
| Q1-2025 | $1.03B ▼ | $2.84B ▼ | $706.22M ▲ | $2.13B ▼ |
| Q4-2024 | $1.11B ▼ | $2.95B ▼ | $703.49M ▲ | $2.24B ▼ |
| Q3-2024 | $1.19B | $2.96B | $684.86M | $2.28B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $193.58M ▲ | $290.32M ▲ | $25.41M ▼ | $-103.86M ▲ | $169.72M ▲ | $288.84M ▲ |
| Q2-2025 | $184.85M ▲ | $48.99M ▼ | $248.03M ▲ | $-316.34M ▼ | $-19.32M ▲ | $48.99M ▼ |
| Q1-2025 | $159.62M ▲ | $211.44M ▼ | $49.76M ▲ | $-294.82M ▼ | $-33.62M ▲ | $188.99M ▼ |
| Q4-2024 | $139.86M ▲ | $240.26M ▼ | $-93.2M ▲ | $-188.03M ▼ | $-40.97M ▼ | $226.29M ▼ |
| Q3-2024 | $117.97M | $271.34M | $-217.15M | $5.7M | $59.89M | $262.14M |
Revenue by Products
| Product | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Collaboration | $60.00M ▲ | $250.00M ▲ | $40.00M ▼ | $50.00M ▲ |
 License | $60.00M ▲ | $240.00M ▲ | $40.00M ▼ | $50.00M ▲ |
 Product | $480.00M ▲ | $950.00M ▲ | $510.00M ▼ | $520.00M ▲ |
 Product Gross | $650.00M ▲ | $1.31Bn ▲ | $720.00M ▼ | $750.00M ▲ |
 Product Sales Discounts And Allowances | $-170.00M ▲ | $0 ▲ | $-210.00M ▼ | $-230.00M ▼ |
 Service | $0 ▲ | $10.00M ▲ | $0 ▼ | $0 ▲ |
Revenue by Geography
| Region | Q3-2024 | Q4-2024 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 Europe | $50.00M ▲ | $40.00M ▼ | $30.00M ▼ | $40.00M ▲ |
 JAPAN | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 UNITED STATES | $480.00M ▲ | $520.00M ▲ | $520.00M ▲ | $520.00M ▲ |
CEO
Michael M. Morrissey
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 306
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
TD Cowen
Buy
Truist Securities
Buy
Citigroup
Buy
JMP Securities
Market Outperform
Leerink Partners
Outperform
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
BLACKROCK INC.
Shares:33.5M
Value:$1.52B
BLACKROCK, INC.
Shares:29.37M
Value:$1.33B
VANGUARD GROUP INC
Shares:26.06M
Value:$1.18B
Summary
Showing Top 3 of 770